Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 12:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy

NCT01469156
Conditions
Polypoidal Choroidal Vasculopathy
Interventions
ranibizumab 0.5 or 2.0 mg/0.05 cc
Drug
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Augusta, Georgia
Conditions
Diabetic Macular Edema, Uveitic Macular Edema
Interventions
RO7200220, Ranibizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
19
States / cities
Beverly Hills, California • Oxnard, California • Palm Desert, California + 16 more
Conditions
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
Interventions
DS-7080a, Ranibizumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 9 more
Conditions
Eye Diseases, Macular Degeneration, Retinal Diseases, Retinal Degeneration, Neovascularization, Pathologic
Interventions
OPT-302, Lucentis™
Drug
Lead sponsor
Opthea Limited
Industry
Eligibility
50 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 11 more
Conditions
PCV, Polypoidal Choroidal Vasculopathy
Interventions
high-dose ranibizumab, ranibizumab
Drug
Lead sponsor
Hawaii Pacific Health
Other
Eligibility
25 Years to 95 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Honolulu, Hawaii • ‘Aiea, Hawaii
Conditions
Choroidal Melanoma
Interventions
Ranibizumab 2 mg, 0.5 mg Ranibizumab
Drug
Lead sponsor
New England Retina Associates
Other
Eligibility
50 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Hamden, Connecticut
Conditions
Wet Macular Degeneration, Macular Degeneration, Retinal Pigment Epithelial Detachment
Interventions
ranibizumab
Drug
Lead sponsor
Anne Fung MD
Other
Eligibility
50 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
Conditions
Neovascularization, Choroidal, Macular Degeneration, Age-Related
Interventions
Faricimab, Ranibizumab, Sham Procedure
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 22 more
Conditions
Clinically Significant Diabetic Macular Edema
Interventions
ranibizumab
Drug
Lead sponsor
Philip J. ferrone, M.D.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Great Neck, New York • Hauppauge, New York
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone intravitreal implant (0.7 mg), Intravitreal anti-VEGF injection
Drug
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Bakersfield, California • Oxnard, California • Santa Barbara, California + 1 more
Conditions
Diabetic Macular Edema
Interventions
ranibizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
13
States / cities
Beverly Hills, California • La Jolla, California • Los Angeles, California + 10 more
Conditions
AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Interventions
ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
Genetic · Biological
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
107
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more
Conditions
Choroidal Neovascularization
Interventions
Faricimab, Ranibizumab, Sham Procedure
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
52
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 46 more
Conditions
Age-related Macular Degeneration
Interventions
AGN-150998, ranibizumab, Sham Injection
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Radiation Retinopathy
Interventions
0.5 mg ranibizumab, Targeted Retinal Photocoagulation (TRP)
Drug · Procedure
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
4
States / cities
Dallas, Texas • Houston, Texas • Katy, Texas + 1 more
Conditions
Diabetic Macular Edema (DME)
Interventions
AKB-9778, ranibizumab, Placebo, Sham
Drug
Lead sponsor
Aerpio Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
39
States / cities
Pheonix, Arizona • Tucson, Arizona • Arcadia, California + 35 more
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Ranibizumab for Diabetic Macular Edema

NCT01982435
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Justis Ehlers
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Cleveland, Ohio • Mayfield Heights, Ohio
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Fovista™, Lucentis®, Avastin®, Eylea®
Drug
Lead sponsor
Retinal Consultants of Arizona
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Macular Degeneration
Interventions
Zifibancimig, Ranibizumab, Port Delivery Platform
Drug · Device
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
36
States / cities
Mesa, Arizona • Phoenix, Arizona • Encino, California + 32 more
Conditions
Retinal Diseases, Telangiectasis
Interventions
ranibizumab 2.0mg
Drug
Lead sponsor
Eye Center of Northern Colorado, P.C.
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Fort Collins, Colorado
Conditions
Age-Related Macular Degeneration (AMD)
Interventions
PAN-90806 Ophthalmic Solution, Lucentis
Drug
Lead sponsor
PanOptica, Inc.
Industry
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
22
States / cities
Colorado Springs, Colorado • Winter Haven, Florida • Shawnee Mission, Kansas + 19 more
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Verteporfin Photodynamic Therapy, Ranibizumab, Verteporfin Placebo, Ranibizumab Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more
Conditions
Diabetic Macular Edema
Interventions
iCo-007 350 mcg, iCo-007 700 mcg, iCo-007 350 mcg and Laser, Ranibizumab and iCo-007 350 mcg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Completed Phase 2 Interventional Results available

Ranibizumab and Bevacizumab for Diabetic Macular Edema

NCT01610557
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab, Bevacizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland